Tempest Therapeutics (TPST) Non-Current Debt (2017 - 2025)
Tempest Therapeutics (TPST) posted Non-Current Debt of $4.2 million for Q1 2025, down 34.38% sequentially from $6.4 million in Q4 2024, and up 1.45% YoY from $4.1 million in Q1 2024.
Tempest Therapeutics (TPST) Non-Current Debt (2017 - 2025) Analysis & Trends
Tempest Therapeutics has reported Non-Current Debt for 9 years, with the latest figure at $4.2 million in Q1 2025.
- Quarterly Non-Current Debt rose 1.45% year-over-year to $4.2 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $4.2 million (up 1.45% YoY) and the FY2024 annual result came in at $6.4 million, up 2.17% from the prior year.
- Non-Current Debt slipped to $4.2 million in Q1 2025 per TPST's latest filing, from $6.4 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $15.3 million in Q3 2022 and troughed at $2.0 million in Q2 2024.
- A 5-year average of $10.3 million and a median of $10.4 million in 2022 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2021 and 2024: Non-Current Debt jumped 13599.09% in 2021, then slumped 73.17% in 2024.
- Over 5 years, Non-Current Debt stood at $15.1 million in 2021, then plunged by 31.18% to $10.4 million in 2022, then tumbled by 39.6% to $6.3 million in 2023, then rose by 2.17% to $6.4 million in 2024, then plunged by 34.38% to $4.2 million in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered $4.2 million, $6.4 million, and $8.5 million for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 8.96 Bn |
| 10 | Tempest Therapeutics | 4.23 Mn | 3.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 4.20 Mn |
| Dec 31, 2024 | 6.40 Mn |
| Sep 30, 2024 | 8.50 Mn |
| Jun 30, 2024 | 2.01 Mn |
| Mar 31, 2024 | 4.14 Mn |
| Dec 31, 2023 | 6.26 Mn |
| Sep 30, 2023 | 10.50 Mn |
| Jun 30, 2023 | 7.48 Mn |
| Mar 31, 2023 | 8.94 Mn |
| Dec 31, 2022 | 10.37 Mn |
| Sep 30, 2022 | 15.34 Mn |
| Jun 30, 2022 | 15.30 Mn |
| Mar 31, 2022 | 15.13 Mn |
| Dec 31, 2021 | 15.07 Mn |
| Sep 30, 2021 | 15.01 Mn |
| Jun 30, 2021 | 14.92 Mn |
| Mar 31, 2021 | 15.07 Mn |
| Jun 30, 2020 | 168,000.00 |
| Mar 31, 2020 | 110,000.00 |
| Dec 31, 2019 | 168,000.00 |